Insider Buying: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Buys 10,000 Shares of Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Director John B. Bode purchased 10,000 shares of the stock in a transaction on Wednesday, March 19th. The shares were purchased at an average cost of $7.96 per share, with a total value of $79,600.00. Following the transaction, the director now owns 40,000 shares of the company’s stock, valued at $318,400. This trade represents a 33.33 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Zevra Therapeutics Price Performance

Shares of ZVRA remained flat at $8.01 during trading on Friday. The company’s stock had a trading volume of 1,681,145 shares, compared to its average volume of 582,031. The company has a market cap of $433.47 million, a P/E ratio of -4.07 and a beta of 1.98. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The business’s fifty day moving average price is $7.90 and its two-hundred day moving average price is $8.17. Zevra Therapeutics, Inc. has a one year low of $4.20 and a one year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The company had revenue of $12.00 million during the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. As a group, equities analysts forecast that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ZVRA shares. Canaccord Genuity Group lifted their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 13th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. JMP Securities set a $18.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Finally, Guggenheim increased their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, March 13th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $22.29.

Hedge Funds Weigh In On Zevra Therapeutics

Several large investors have recently modified their holdings of ZVRA. BNP Paribas Financial Markets acquired a new stake in Zevra Therapeutics during the fourth quarter valued at approximately $53,000. XTX Topco Ltd acquired a new position in shares of Zevra Therapeutics in the 3rd quarter worth approximately $94,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Zevra Therapeutics in the 4th quarter valued at approximately $94,000. Intech Investment Management LLC acquired a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at approximately $95,000. Finally, Virtu Financial LLC bought a new position in Zevra Therapeutics during the third quarter worth $127,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.